SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
SK Biopharm submits NDA of epilepsy drug to China
South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...
SK Biopharm targets $311 mn for Cenobamate US sales
South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...
SK Biopharm gears up to boost epilepsy drug sales in Europe
SK Biopharmaceuticals Co. is gearing up to explore the European market for its flagship epilepsy drug Cenobamate, while looking for new mergers and ...
SK Biopharma’s Cenobamate US patent extended by 2032
South Korea's SK Biopharmaceuticals announced on Friday an extension of its US patent for the epilepsy treatment Cenobamate, now set to expire on Oc...
SK Biopharm to export epilepsy drug tech to Middle Eastern firm
South Korea's SK Biopharmaceuticals announced on Friday a strategic tie-up with Hikma MENA FZE, marking the introduction of its new epilepsy medicat...
SK Biopharmaceuticals gets OK to sell epilepsy drug in Canada
South Korea's SK Biopharmaceuticals has received approval in Canada to sell its new epilepsy drug Cenobamate under the product name Xcopri. Having e...
Another Foreigner Detained in China, This Time a Korean Soccer Pro
SINGAPORE—Chinese police have detained a South Korean soccer player on allegations of bribery, the latest in a spate of enforcement actions af...
Terra co-founder Do Kwon’s $177 million assets in Korea under seizure
Terraform Labs co-founder Do Kwon, the mastermind behind the Terra-Luna cryptocurrency collapse, has had most of his assets in South Korea frozen, a...
SK Biopharmaceuticals gets marketing approval for epilepsy drug in Israel
South Korea’s SK Biopharmaceuticals said on Wednesday that the Israeli Ministry of Health has approved the company's new drug application (NDA...
SK Biopharmaceuticals wins Red Dot award for 2 devices
South Korea’s SK Biopharmaceuticals on Tuesday said two of its self-developed wearable devices won the main prize in the health care category ...
SK Biopharm holds sales meeting for marketing Cenobamate in US
On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The p...
SK Biopharm begins clinical trials of wearable device for detecting epilepsy
SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict ep...
SK Biopharmaceuticals launches epilepsy drug in France
South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...
SK Biopharma's epilepsy treatment posts impressive growth in US
South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...
SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma
South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...
SK invests in US digital healthcare firm Cala Health
South Korea's SK Biopharmaceuticals Co. has dipped its toes into the rapidly growing digital healthcare market by investing in Cala Health, a US-bas...
SK Biopharm releases epilepsy treatment in UK
South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...
SK Biopharm aims to make it to global top 10 healthcare firms by 2030
South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...
